Fingolimod: A review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

Douglas R. Jeffery, Kottil W Rammohan, Kathleen Hawker, Edward Fox

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocytes. Here we review the current literature to describe the mechanism of action of fingolimod in the context of its well-established clinical efficacy and safety profile. Understanding of the mechanisms behind any non-therapeutic effects of fingolimod facilitates their prediction and management in the clinical setting.

Original languageEnglish (US)
Pages (from-to)31-44
Number of pages14
JournalExpert Review of Neurotherapeutics
Volume16
Issue number1
DOIs
StatePublished - Jan 2 2016

Keywords

  • efficacy
  • Fingolimod
  • mechanism of action
  • multiple sclerosis
  • non-therapeutic effects
  • safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Fingolimod: A review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this